Cargando…

Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction

This review presents the last decade of studies on the synthesis of various types of small-molecule inhibitors of the p53– Mouse double minute 2 homolog (MDM2) protein–protein interaction. The main focus is placed on synthetic approaches to such molecules, their cytotoxicity, and MDM2 binding charac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beloglazkina, Anastasia, Zyk, Nikolai, Majouga, Alexander, Beloglazkina, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179467/ https://www.ncbi.nlm.nih.gov/pubmed/32156064 http://dx.doi.org/10.3390/molecules25051211

Ejemplares similares

Synthesis of 1,3-diaryl-spiro[azetidine-2,3′-indoline]-2′,4-diones via the Staudinger reaction: cis- or trans-diastereoselectivity with different addition modes
por: Filatov, Vadim, et al.
Publicado: (2020)

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective
por: Zhao, Yujun, et al.
Publicado: (2014)

Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate
por: Machulkin, Aleksei E., et al.
Publicado: (2022)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles
por: Kukushkin, Maksim, et al.
Publicado: (2021)

Aβ-Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications
por: Krasnovskaya, Olga, et al.
Publicado: (2022)

Tacrine-Based Hybrids: Past, Present, and Future
por: Bubley, Anna, et al.
Publicado: (2023)

Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors
por: Cheng, Xiyao, et al.
Publicado: (2022)

Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen
por: Petrov, Stanislav A., et al.
Publicado: (2020)

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions
por: Blackburn, Tim J., et al.
Publicado: (2013)

Copper Coordination Compounds as Biologically Active Agents
por: Krasnovskaya, Olga, et al.
Publicado: (2020)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
por: Xue, Xin, et al.
Publicado: (2018)

Synthesis, (123)I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures
por: Hasnowo, Lutfi A., et al.
Publicado: (2023)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

Synthesis of Prostate-Specific Membrane Antigen-Targeted Bimodal Conjugates of Cytotoxic Agents and Antiandrogens and Their Comparative Assessment with Monoconjugates
por: Zyk, Nikolai Y., et al.
Publicado: (2023)

Metals in Imaging of Alzheimer’s Disease
por: Krasnovskaya, Olga, et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
por: Ivanenkov, Yan A., et al.
Publicado: (2023)

Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
por: Frosi, Y., et al.
Publicado: (2019)

DIMP53‐1: a novel small‐molecule dual inhibitor of p53–MDM2/X interactions with multifunctional p53‐dependent anticancer properties
por: Soares, Joana, et al.
Publicado: (2017)

Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs
por: Spector, Daniil, et al.
Publicado: (2022)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein–protein interactions identifies a novel putative Mdm2-binding site in p53
por: Wong, Jin Huei, et al.
Publicado: (2017)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53–MDM2/MDMX Protein–Protein Interactions
por: Sang, Peng, et al.
Publicado: (2020)

cis-Diastereoselective Synthesis of Spirooxindolo-β-Lactams by Staudinger Cycloaddition with TsCl as Activating Co-reagent
por: Filatov, Vadim E., et al.
Publicado: (2021)

Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years
por: Petrov, Stanislav A., et al.
Publicado: (2022)

Correction to α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53–MDM2/MDMX Protein–Protein Interactions
por: Sang, Peng, et al.
Publicado: (2020)

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors
por: Dickinson, Eleanor R., et al.
Publicado: (2015)

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
por: Yi, Hanjie, et al.
Publicado: (2018)

Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability
por: Novotortsev, Vladimir K., et al.
Publicado: (2021)

Correction: Environment-sensitive turn-on fluorescent probes for p53–MDM2 protein–protein interaction
por: Liu, Tingting, et al.
Publicado: (2017)

8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction
por: Pettersson, Mariell, et al.
Publicado: (2015)

Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017)

p53 AND MDM2 PROTEIN EXPRESSION IN ACTINIC CHEILITIS
por: de Freitas, Maria da Conceição Andrade, et al.
Publicado: (2008)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
por: Lakoma, A, et al.
Publicado: (2015)

[4+2]-Cycloaddition to 5-Methylidene-Hydantoins and 5-Methylidene-2-Thiohydantoins in the Synthesis of Spiro-2-Chalcogenimidazolones
por: Shybanov, Dmitry E., et al.
Publicado: (2023)

Small Molecules as Protein-Protein Interaction Inhibitors
por: Hajimahdi, Zahra
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e7opbn6pecudvmc55rt1bsgj0b